S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00049400
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : April 3, 2015
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Southwest Oncology Group

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : September 2006
  Actual Study Completion Date : December 2007
Publications of Results:
Takimoto CH, Liu PY, Lenz H, et al.: A phase I pharmacokinetic (PK) study of the epothilone B analogue, ixabepilone (BMS-247550) in patients (pts) with advanced malignancies and varying degrees of hepatic impairment. A SWOG Early Therapeutics Committee and NCI Organ Dysfunction Working Group Trial. [Abstract] J Clin Oncol 24 (Suppl 18): A-2004, 2006.